Latest Nodule Stories
SOUTH SAN FRANCISCO, Calif., April 12, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer. "We are delighted to welcome Shelly Guyer to the Veracyte team," said Bonnie Anderson, Veracyte's cofounder and chief executive officer. "Her extensive background in the life science and finance industries will be critical as we experience...
SOUTH SAN FRANCISCO, Calif., March 12, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced new study findings showing that when BRAF V600E mutation testing was conducted on ambiguous thyroid nodule samples that were subsequently classified as benign by the company's Afirma Gene Expression Classifier, no BRAF-positive cases - that would suggest cancer - were found. The study appears online in the...
SOUTH SAN FRANCISCO, Calif., March 8, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that UnitedHealthcare, one of the nation's largest private health insurers, has issued a positive medical coverage policy for the Afirma® Gene Expression Classifier for use in assessing thyroid nodule fine needle aspirate (FNA) biopsies that are indeterminate - not clearly benign or malignant following...
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma. The new NCCN Guidelines indicate that, when a thyroid nodule fine needle aspiration (FNA) result is indeterminate using...
Penn Medicine editorial suggests 25,000 unnecessary surgeries can be avoided A new test can be used to identify low-risk thyroid nodules, reducing unnecessary surgeries for people with thyroid nodules that have indeterminate results after biopsy. The results of the multi-center trial, which includes researchers from the Perelman School of Medicine at the University of Pennsylvania, appear online in the New England Journal of Medicine. Ultrasound-guided fine-needle aspiration biopsies...
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that new data from researchers at Johns Hopkins University School of Medicine suggest that routine use of its Afirma® Gene Expression Classifier for clarifying inconclusive results on thyroid nodule fine needle aspiration (FNA) samples will improve patient care and save the healthcare system money. According to the...
JACKSONVILLE, Fla., May 19 /PRNewswire-USNewswire/ -- Three of the world's most respected medical associations for the treatment of thyroid disease recently issued joint guidelines for the diagnosis and management of thyroid nodules. The American Association of Clinical Endocrinologists (AACE), the Associazione Medici Endocrinologi (AME) and European Thyroid Association (ETA) jointly published the guidelines online this week, and the executive summary will be published in the next issue of...
